Formulation Evaluation of Extended-Release Solid Dispersion of Metformin Hydrochloride

Patil, S. A.; Kuchekar, Bhanudas S.; Chabukswar, Anuruddha R.; Jagdale, Swati

doi:10.4103/0975-1483.63147

Cited by 27 publications

(24 citation statements)

References 20 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solid dispersions of metformin hydrochloride developed with methocel K100M were investigated also as alternative carrier for the antidiabetic molecule. These carriers prepared by solvent evaporation and co-grinding method revealing that the polymer ratio affected the drug release rate 41 . Similar solid dispersions were also formulated by solvent evaporation and closed melt method, using Compritol 888 ATO as the polymer.…”

Section: Pharmaceutical Formulations For the Delivery Of Metforminmentioning

confidence: 99%

Diabetes Mellitus: A Review on Pathophysiology, Current Status of Oral Pathophysiology, Current Status of Oral Medications and Future Perspectives

Okur¹,

Karantas²,

Sıafaka³

2017

actapharm

View full text Add to dashboard Cite

Section: Pharmaceutical Formulations For the Delivery Of Metforminmentioning

confidence: 99%

Diabetes Mellitus: A Review on Pathophysiology, Current Status of Oral Pathophysiology, Current Status of Oral Medications and Future Perspectives

Okur¹,

Karantas²,

Sıafaka³

2017

actapharm

View full text Add to dashboard Cite

“…In the literature can be found also report on the application of solid dispersions for the controlled release of drugs [7]. Patil et al [8] have used the SDs containing a polymer blend, such as hydroxypropylcellulose and ethylcellulose that allowed possible to precisely control the rate of release of watersoluble drug. The improvement of drug dissolution profile from solid dispersions is observed, when the ratio of carriers in solid dispersions increased, and the drug was dispersed better and the drug crystallinity decreased.…”

Section: Introductionmentioning

confidence: 99%

Pluronic F127 as a suitable carrier for preparing the imatinib base solid dispersions and its potential in development of a modified release dosage forms

Karolewicz

Gajda

Gòrniak

et al. 2017

J Therm Anal Calorim

View full text Add to dashboard Cite

In recent years, considerable attention focuses on making sustained release dosage forms also containing solid dispersions. The objective of this study is evaluation of imatinib base (IMA) solid dispersion physicochemical properties which can be useful to controlled release solid dosage formation. The solid dispersions were obtained by kneading method, containing of 10-90% w/w Pluronic F127 (PLU). Drug dissolution test was determined by rotating-disc system method in 0.1 M hydrochloric acid (pH 1.2) and phosphate buffer (pH 6.8). XRD, DSC, FTIR, and SEM observations were performed to evaluate the physical characteristics of solid dispersions. These studies showed that there was no chemical interaction of the IMA with PLU in the solid state and revealed that IMA and PLU form a simple eutectic phase diagram. Our research has shown that the dynamics of the release of imatinib base from solid dispersions with Pluronic F127 depends on the pH of dissolution medium. At pH 1.2, the presence of polymer in solid dispersion causes delaying of drug release due to formation a viscous gel layer, whereas at pH 6.8 significant enhancement of the drug dissolution rate from solid dispersions has been observed compared to pure IMA. The highest improvement was observed in solid dispersions containing 20 and 30% w/w polymer. The present investigation confirmed that the hydrophilic polymer Pluronic F127 could be applied as a suitable matrix to design modified release formulations of imatinib base.

show abstract

“…The CR effects vary not only with the amount of the polymer but also with the SD preparation technique. SDs prepared by solvent evaporation using methocel K100M can prolong the release of metformin for 10 h at 80% concentration and by the cogrinding method at 83% concentration of the polymer (132).…”

Section: Traditional Methodsmentioning

confidence: 99%

Controlled Release Systems Containing Solid Dispersions: Strategies and Mechanisms

Tran

Park

et al. 2011

Pharm Res

View full text Add to dashboard Cite

In addition to a number of highly soluble drugs, most new chemical entities under development are poorly water-soluble drugs generally characterized by an insufficient dissolution rate and a small absorption window, leading to the low bioavailability. Controlled-release (CR) formulations have several potential advantages over conventional dosage forms, such as providing a uniform and prolonged therapeutic effect to improve patient compliance, reducing the frequency of dosing, minimizing the number of side effects, and reducing the strength of the required dose while increasing the effectiveness of the drug. Solid dispersions (SD) can be used to enhance the dissolution rate of poorly water-soluble drugs and to sustain the drug release by choosing an appropriate carrier. Thus, a CR-SD comprises both functions of SD and CR for poorly water-soluble drugs. Such CR dosage forms containing SD provide an immediately available dose for an immediate action followed by a gradual and continuous release of subsequent doses to maintain the plasma concentration of poorly water-soluble drugs over an extended period of time. This review aims to summarize all currently known aspects of controlled release systems containing solid dispersions, focusing on the preparation methods, mechanisms of action and characterization of physicochemical properties of the system.

show abstract

Formulation Evaluation of Extended-Release Solid Dispersion of Metformin Hydrochloride

Cited by 27 publications

References 20 publications

Diabetes Mellitus: A Review on Pathophysiology, Current Status of Oral Pathophysiology, Current Status of Oral Medications and Future Perspectives

Diabetes Mellitus: A Review on Pathophysiology, Current Status of Oral Pathophysiology, Current Status of Oral Medications and Future Perspectives

Pluronic F127 as a suitable carrier for preparing the imatinib base solid dispersions and its potential in development of a modified release dosage forms

Controlled Release Systems Containing Solid Dispersions: Strategies and Mechanisms

Contact Info

Product

Resources

About